XKH001 Placebo Injection

DRUG3 trials

Sponsors

Beijing Kanova Biopharmaceutical Co., LTD, Zhejiang Kanova Biopharmaceutical Co., LTD

Conditions

AsthmaAtopic DermatitisHealthy Adult

Phase 1

XKH001 Injection in Healthy Subjects

CompletedNCT05991661

Beijing Kanova Biopharmaceutical Co., LTDAsthma

Start: 2023-05-12End: 2024-03-29Updated: 2026-03-05

Bridging Study of XKH001 in Healthy Adult Caucasian Participants

Not yet recruitingNCT07757659

Zhejiang Kanova Biopharmaceutical Co., LTDHealthy Adult

Start: 2026-08-01End: 2027-08-01Target: 2Updated: 2026-08-11

Phase 2

Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

Not yet recruitingNCT07054736

Zhejiang Kanova Biopharmaceutical Co., LTDAtopic Dermatitis

Start: 2025-08-31End: 2025-12-01Target: 120Updated: 2025-07-08

Related Papers

First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers

Expert Opinion on Investigational Drugs2025-01-162 citations